Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA), for drug-medical device combination products at its injectable facility in Nagpur, India. The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024.

Nilesh Gupta, Managing Director, Lupin said, “We are very pleased to have received the EIR from the US FDA for drug-device combination products at our Nagpur injectable facility. We remain committed to producing complex generic and essential products that address unmet needs."